Osteoporosis and breast cancer

Joint Bone Spine

Volumn 71, Issue 2, 2004, Pages 102-110

  Fontanges, Elisabeth ^a   Fontana, Aurélie ^a   Delmas, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphosphonates; Estrogens; Hormone replacement therapy; Selective estrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; CLODRONIC ACID; DOXORUBICIN; ESTROGEN; GLUCOCORTICOID; IFOSFAMIDE; IPRIFLAVONE; ISOFLAVONE; LYTOS; METHOTREXATE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHONIC ACID DERIVATIVE; PHYTOESTROGEN; PRASTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; TIBOLONE; ZOLEDRONIC ACID;

BONE TISSUE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG POTENCY; ESTROGEN THERAPY; FRAGILITY FRACTURE; FRANCE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MENOPAUSE; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; VOMITING;

EID: 1642503119     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.02.001     Document Type: Short Survey

References (70)

1. Friedlaender G.E., Tross R.B., Doganis A.C., Kinkwood J.M., Baron R. Effects of chemotherapeutic agents on bone. J Bone Jt Surg. 66-A:1984;602-607.
2. Virolainen P., Inoue N., Frassica F.G., Chao E.Y. The effect of a doxorubicin, cisplatin and ifosfamide combination chemotherapy on bone turnover. Anticancer Res. 22:2002;1971-1975.
3. Lukert B.P. Glucocorticoid and drug-induced osteoporosis. 3rd ed Favus M.J. Primer on the metabolic bone diseases and disorders of mineral metabolism. 1996;278-282 Lippincott-Raven, Philadelphia, NY.
4. Bruning P.F., Pit M.J., de Jong-Bakker M., Van den Ende A., Hart A., Van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 61:1990;308-310.
5. Delmas P.D., Balena R., Confavreux E., Hardoin C., Hardy P., Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo-controlled study. J Clin Oncol. 15:1997;955-962.
6. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 15:1997;1341-1347.
7. Powles T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 14:1996;78-84.
8. Kristensen B., Ejlertsen B., Dalgaard P., Larsen L., Holmegaard S.N., Transbol I., et al. Tamoxifen and bone metabolism in post menopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 12:1994;992-997.
9. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl J Med. 326:1992;852-856.
10. The Atac Trialist Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 359:2002;2131-2139.
11. Cummings S.R., Melton L.J. III. Epidemiology and outcomes of osteoporotic fractures. Lancet. 359:2002;1761-1767.
12. Ettinger B., Pressman A., Sklarin P., Bauer D.C., Cauley J.A., Cummings S.R. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the Study of Osteoporotic Fractures. J Clin Endocrinol Metab. 83:1998;2239-2243.
13. Cummings S.R., Browner W.S., Bauer D.B., Stone K., Ensrud K., Jamal S., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. New Engl J Med. 339:1998;733-738.
14. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turn-over, endogenous hormones and the risk of fractures in post-menopausal women. J Bone Miner Res. 15:2000;1526-1536.
15. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture risk in elderly women. The EPIDOS Prospective Study. J Bone Miner Res. 11:1996;1531-1538.
16. Stone K., Bauer D.C., Black D.M., Skalarin P., Ensrud K.E., Cummings S.R. Hormonal predictors of bone loss in elderly women: a prospective study. Bone Miner Res. 13:1998;1167-1174.
17. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 359:2002;1929-1936.
18. Black D.M., Steinbuch M., Palermo P., Dargent-Molina P., Lindsay R., Hoseyni M.S., et al. An assessment tool for predicting fracture risk in post-menopausal women. Osteoporosis Int. 12:2001;519-528.
19. Roux C., Pols H., Watts N.B., Ringe J., Giraudeau B., Horlait S., et al. L'ostéoporose « inattendue » Resultats de l'étude Impact [abstract]. Rev Rhum. 68:2001;995.
20. Cauley J.A., Lucas F.L., Kuller L.H., Vogt M.T., Browner W.S., Cummings S.R. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. J Am Med Assoc. 276:1996;1404-1408.
21. Zhang Y., Kiel D.P., Kreger B.E., Cupples L.A., Ellison R.C., Dorgan J.F., et al. Bone mass and the risk of breast cancer among postmenopausal women. New Engl J Med. 336:1997;611-617.
22. Cauley J.A., Lucas F.L., Kuller L.H., Stone K., Browner W.S., Cummings S.R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 130:1999;270-277.
23. Rosner B., Colditz G.A., Willette W.C. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 139:1994;819-835.
24. Stoll B.A. Upper abdominal obesity, insulin resistance and cancer risk. Int J Obesity. 2002;747-753.
25. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. J Am Med Assoc. 281:1999;2189-2197.
26. Russell G. Bone metabolism and its regulation. Eastell R. Bone markers, biochemical and clinical perspectives. 2001;15-16 Martin Dunitz.
27. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial Writing group for the Women's Health Initiative investigators. J Am Med Assoc. 288:2002;321-323.
28. Delmas P.D. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporosis Int. 7:(Suppl 1):1997;S3-S7.
29. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet. 359:2002;2018-2026.
30. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 122:1995;9-16.
31. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W., Moskowitz M.A. Hip fracture and the use of estrogen in postmenopausal women. New Engl J Med. 317:1987;1169-1174.
32. Lufkin E.G., Wahner H.W., O' Fallon W.M., Hodgson S.F., Kotowicz M.A., Lane A.W., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 117:1992;1-9.
33. Randell K.M., Honkanen R.J., Kröger H., Saarikoski S. Does hormone replacement therapy prevent fractures in early postmenopausal women? J Bone Miner Res. 17:2002;528-533.
34. Togerson D.J., Bell-Syer S.E.M. Hormone replacement therapy and prevention of non-vertebral fractures. A meta-analysis of randomized trials. J Am Med Assoc. 285:2001;2891-2897.
35. Marcelli C. Bone loss prevention and breast cancer risk. Jt Bone Spine. 67:2000;143-145.
36. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med. 332:1995;1589-1593.
37. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc. 283:2000;485-491.
38. Roos R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:2000;328-332.
39. Collaborative group on hormonal factors in breast cancer and hormone replacement therapy. collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
40. Steinberg K.K., Thacker S.B., Smith J. A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc. 265:1991;1985-1990.
41. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. New Engl J Med. 337:1997;1641-1647.
42. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: 4-year results from a randomized clinical trial. J Clin Endocrinol Metab. 87:2002;3609-3617.
43. Cummings S.R., Eckert S., Kruegor K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on the risk of breast cancer in postmenopausal women. J Am Med Assoc. 281:1999;2189-2197.
44. Cauley J.A., Norton L., Lippman L.E., Eckert S., Krueger K.A., Purdie D.W., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 65:2001;125-134.
45. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc. 282:1999;1344-1352.
46. Reginster J.Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int. 11:2000;83-91.
47. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Newitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
48. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barret-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. J Am Med Assoc. 280:1998;2077-2082.
49. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hockberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab. 85:2000;4118-4124.
50. Paterson A.H.G., Powles T.J., Kanis J.A., Mc Closkey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastasis from breast cancer. J Clin Oncol. 11:1993;59-65.
51. Hortobagyi G.N., Theriault R., Porter L., Blayney D., Lipton A., Sinoff C., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med. 335:1996;1785-1791.
52. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7:2001;377-387.
53. Powles T., Paterson S., Kanis J.A., Mc Closkey E., Ashley S., Tidy A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 20:2002;3219-3224.
54. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med;344:1434-41.
55. Marie P.J., Ammann P., Boivin G., Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 69:2001;121-129.
56. Meunier P.J., Lorenc R.S., Smith I.G., Roces-Varela A., Pasariello R., Bonidan O., et al. Strontium ranelate: new efficient anti-osteoporotic agent for treatment of vertebral osteoporosis in postmenopausal women. Osteoporosis Int. 13:(Suppl 3):2002;66.
57. Reginster J.Y., Sawicki A., Devogelaer J.P., Padrino J.M., Kaufman J.M., Doyle D.V., et al. Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Osteoporosis Int. 13:(Suppl 3):2002;O14.
58. Villareal D.T., Hollosky J.O., Kohrt W.N. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol. 53:2000;561-568.
59. Labrie F., Diamond P., Cusan L., Gomez J.L., Belanger A., Candas B. Effect of 12 month DHEA replacement therapy on bone, vagina and endometrium in post menopausal women. J Clin Endocrinol Metab. 82:1997;3498-3505.
60. Beaulieu E.E., Thomas G., Legrain S., Lalhou N., Roger M., Faubcouneau V., et al. DHEA, DHEA sulfate and aging: contribution of DHEA age study to a sociobiomedical issue. Proc Natl Acad Sci USA. 97:2000;4279-4284.
61. Cormier C., Souberbielle J.C., Kahan A. DHEA in bone and joint diseases. Jt Bone Spine. 68:2001;588-594.
62. Gallagher J.C., Baylink D.J., Freeman R., McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab. 86:2001;4717-4726.
63. Bjarnason N.H., Bjarnason K., Jaarbo J., Rosenquist C., Christiansen C. Tibolone prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 81:1996;2419-2422.
64. Reginster J.Y. Post-menopausal hormonal therapy: conventional replacement therapy or tibolone? Effects on bone. J Gynecol Obstet Biol Reprod. 31:2002;541-549.
65. Horiuchi T., Onouchi T., Takahashi M., Ito H., Orimo H. Effect of soy on bone metabolism in post-menopausal Japanese women. Osteoporosis Int. 11:2000;721-724.
66. Gennari C., Agnusdei D., Crepaldi G., Isia G., Mazzuoli G., Ortolani S., et al. Effect of ipriflavone - a synthetic derivative of natural isoflavones on bone mass loss in the early years after menopause. Menopause. 5:1998;9-15.
67. Ingram D., Sanders K., Kolybaba M., Lopez D. Case-control study of phyto-estrogens and breast cancer. Lancet. 350:1997;990-994.
68. Alexandersen P., Toussaint A., Christiansen C., Devogelaer J.P., Roux C., Fechtenbaum J., et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomised control trial. J Am Med Assoc. 285:2001;1482-1488.
69. Consensus statement: treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab. 83:1998;1993-2000.
70. Spicer D.V., Pike M.C. Hormone replacement after breast cancer. Lancet. 342:1993;183-184.